छोड़कर सामग्री पर जाएँ
Suven Pharma, Cohance Lifesciences announce merger

Suven Pharma, Cohance Lifesciences announce merger

The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.

Read More

​ The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals. The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.  Moneycontrol Latest News Read More  

The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.

Platinum Industries#39; IPO sees 99 times subscription on final day, retail book 51x

Platinum Industries#39; IPO sees 99 times subscription on final day, retail book 51x

Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.

Read More

​ Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said. Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.  Moneycontrol Latest News Read More  

Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.

Reduce ICICI Lombard; target of Rs 1650: Emkay Global Financial

Reduce ICICI Lombard; target of Rs 1650: Emkay Global Financial

Emkay Global Financial recommended reduce rating on ICICI Lombard with a target price of Rs 1650 in its research report dated February 28, 2024.

Read More

​ Emkay Global Financial recommended reduce rating on ICICI Lombard with a target price of Rs 1650 in its research report dated February 28, 2024. Emkay Global Financial recommended reduce rating on ICICI Lombard with a target price of Rs 1650 in its research report dated February 28, 2024.  Moneycontrol Latest News Read More  

Emkay Global Financial recommended reduce rating on ICICI Lombard with a target price of Rs 1650 in its research report dated February 28, 2024.

India#39;s GDP growth accelerates to 8.4% in Q3; FY24 growth pegged at 7.6%

India#39;s GDP growth accelerates to 8.4% in Q3; FY24 growth pegged at 7.6%

The first advance estimate of the GDP for 2023-24, released on January 5, had pegged the full-year growth at 7.3 percent.

Read More

​ The first advance estimate of the GDP for 2023-24, released on January 5, had pegged the full-year growth at 7.3 percent. The first advance estimate of the GDP for 2023-24, released on January 5, had pegged the full-year growth at 7.3 percent.  Moneycontrol Latest News Read More  

The first advance estimate of the GDP for 2023-24, released on January 5, had pegged the full-year growth at 7.3 percent.

GPT Healthcare shares close above Rs 200 on debut, climb 8%

GPT Healthcare shares close above Rs 200 on debut, climb 8%

GPT Healthcare traded with volume of 2.07 crore equity shares on the NSE, and 11.58 lakh equity shares on the BSE.

Read More

​ GPT Healthcare traded with volume of 2.07 crore equity shares on the NSE, and 11.58 lakh equity shares on the BSE. GPT Healthcare traded with volume of 2.07 crore equity shares on the NSE, and 11.58 lakh equity shares on the BSE.  Moneycontrol Latest News Read More  

GPT Healthcare traded with volume of 2.07 crore equity shares on the NSE, and 11.58 lakh equity shares on the BSE.

US FDA issues 4 observations for Biocon Biologics#39; insulin facility

US FDA issues 4 observations for Biocon Biologics#39; insulin facility

The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL#39;s customer late last year

Read More

​ The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL#39;s customer late last year The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL#39;s customer late last year  Moneycontrol Latest News Read More  

The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL#39;s customer late last year

US FDA slaps Aurobindo Pharma#39;s Telengana injectable facility with 7 observations

US FDA slaps Aurobindo Pharma#39;s Telengana injectable facility with 7 observations

The company said that these observations are procedural in nature and will be responded to within the stipulated time.

Read More

​ The company said that these observations are procedural in nature and will be responded to within the stipulated time. The company said that these observations are procedural in nature and will be responded to within the stipulated time.  Moneycontrol Latest News Read More  

The company said that these observations are procedural in nature and will be responded to within the stipulated time.

US FDA slaps Aurobindo Pharma#39;s Telangana injectable facility with 7 observations

US FDA slaps Aurobindo Pharma#39;s Telangana injectable facility with 7 observations

The company said that these observations are procedural in nature and will be responded to within the stipulated time.

Read More

​ The company said that these observations are procedural in nature and will be responded to within the stipulated time. The company said that these observations are procedural in nature and will be responded to within the stipulated time.  Moneycontrol Latest News Read More  

The company said that these observations are procedural in nature and will be responded to within the stipulated time.

Platinum Industries#39; IPO sees 98.92 times subscription on final day, retail book 51x

Platinum Industries#39; IPO sees 98.92 times subscription on final day, retail book 51x

Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.

Read More

​ Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said. Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.  Moneycontrol Latest News Read More  

Platinum Industries IPO | In the grey market, Platinum attracted more than 50 percent premium over the upper price band, the market observers said.

Banks struggle to attract deposits as customers chase high return equity-linked products

Banks struggle to attract deposits as customers chase high return equity-linked products

To lure depositors, banks have come with special deposit products and schemes offering higher rate of returns for certain tenures. However, it is going to be tough to compete with higher returns offered by other instruments, experts say.

Read More

​ To lure depositors, banks have come with special deposit products and schemes offering higher rate of returns for certain tenures. However, it is going to be tough to compete with higher returns offered by other instruments, experts say. To lure depositors, banks have come with special deposit products and schemes offering higher rate of returns for certain tenures. However, it is going to be tough to compete with higher returns offered by other instruments, experts say.  Moneycontrol Latest News Read More  

To lure depositors, banks have come with special deposit products and schemes offering higher rate of returns for certain tenures. However, it is going to be tough to compete with higher returns offered by other instruments, experts say.

hi_INहिन्दी